FDA Proposes Policy Change Concerning 5-Year NCE Exclusivity for Certain Fixed-Combination Drugs

by Ropes & Gray LLP
Contact

Prompted by citizen petitions filed by Ropes & Gray and by two other companies, FDA issued draft guidance proposed a change in the Agency’s interpretation of 5-year new chemical entity (“NCE”) exclusivity as applied to certain fixed-combination drug products (“fixed-combinations”). Fixed-combinations are drug products that generally include two or more drug substances (i.e., active ingredients) in a fixed ratio, synthetically combined in a single dosage form. Historically, FDA interpreted the relevant statutory and regulatory provisions to preclude 5-year NCE exclusivity for a fixed-combination that included both a new active moiety a previously approved active moiety. Under FDA’s new interpretation, such a fixed-combination will be eligible for 5-year NCE exclusivity so long as it contains at least one drug substance, no active moiety of which has been previously approved.

Historical Approach

FDA’s long-standing position has been that fixed-combinations are eligible for 5-year NCE exclusivity only if every active moiety in the combination is new – if just one of the active moieties has been approved previously, the fixed-combination is not eligible for 5-year NCE exclusivity. This approach was based on FDA’s interpretation of the 5-year NCE exclusivity provision, which states:

If an application submitted under subsection (b) of this section for a drug, no active ingredient (including any ester or salt of the active ingredient) of which has been approved in any other application under subsection (b) of this section, is approved . . . no application may be submitted under this subsection which refers to the drug for which the subsection (b) application was submitted before the expiration of five years from the date of approval of the application under subsection (b) of this section…[1]

 

The statute thus includes clauses describing both eligibility for 5-year NCE exclusivity (the “eligibility clause”) and the parameters of this exclusivity once it attaches (the “bar clause”). Historically, FDA interpreted the term “drug” in the eligibility clause to mean “drug product,” while it interpreted the term “drug” in the bar clause to mean “drug substance.” Because FDA interpreted “drug” to mean “drug product” in the eligibility clause, a drug product could only be eligible for 5-year NCE exclusivity if “no active ingredient” in the drug product had previously been approved. This led to FDA’s conclusion that fixed-combinations including both a new active ingredient and a previously approved active ingredient were not eligible for 5-year NCE exclusivity.

Citizen Petitions

In 2013, three companies each petitioned FDA to revise its interpretation of 5-year NCE exclusivity with respect to certain fixed-combinations. The petitioners argued that FDA’s interpretation of the word “drug” to mean two different things in the 5-year NCE exclusivity provision was contrary to the statutory language, Congressional intent, and FDA’s own implementing regulations. In addition, the petitioners argued that FDA’s historical approach leads to illogical and arbitrary results by putting undue weight on the order in which a sponsor’s applications are approved in determining their eligibility for 5-year NCE exclusivity.[2] The petitioners also pointed out that FDA’s policy favors the development of a new active ingredient in a single-entity drug product that is cross-labeled for use with another drug product that contains a previously approved active ingredient, as opposed to development of the new active ingredient in a fixed-combination.

Response to Petitions and New Interpretation

In its consolidated response to the three petitions, FDA concluded that the petitioners articulated a reasonable alternative interpretation of the statute and regulations that would be beneficial to the public health. FDA recognized that a change in policy was warranted given recent changes in the field of fixed-combinations. FDA also acknowledged that its historical approach to fixed-combinations could result in suboptimal development strategies.

Accordingly, FDA announced that it is proposing to change its interpretation of 5-year NCE exclusivity to align the exclusivity incentives more closely with FDA’s public health goals. Under this interpretation, the term “drug” in the eligibility clause (and in the regulatory definition of “new chemical entity”) will refer to “drug substance,” not “drug product.” If FDA adopts this interpretation, a 5-year NCE exclusivity determination will be made for each drug substance in a drug product, not for the drug product as a whole. As a result, a fixed-combination drug product that contains a drug substance with a single, new active moiety would be eligible for 5-year NCE exclusivity, even if the fixed-combination also contains a drug substance with a previously approved active moiety.

New Draft Guidance

On the same day that FDA responded to the petitions, it issued new draft guidance proposing and seeking public comment on the new interpretation that would recognize 5-year NCE exclusivity for certain fixed-combinations. FDA stated that if, at the conclusion of the comment period, it is convinced that the proposed new interpretation is appropriate, it will issue final guidance and will adopt the new interpretation. The draft guidance also states that the new interpretation will not apply to fixed-combinations that are approved “prior to adopting the new interpretation.”

FDA will be accepting comments on the draft guidance until April 25, 2014. 

[1] 21 U.S.C. § 355(j)(f)(F)(ii); see also 21 U.S.C. § 355(c)(3)(E)(ii).

[2] Under FDA’s historical interpretation, if a single-entity drug product containing a new active ingredient was approved before a fixed-combination containing the same active ingredient together with a previously approved active ingredient, both the single-entity product and the fixed-combination product could benefit from the single-entity product’s 5-year NCE exclusivity. If the order of approval of these applications were to be reversed, however, neither the fixed combination nor the single-entity drug product would be eligible for 5-year NCE exclusivity.

 

Written by:

Ropes & Gray LLP
Contact
more
less

Ropes & Gray LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.